GSK’s new R&D head bets on genetics with $300 mln 23andMe deal

25 Jul 2018

GlaxoSmithKline's new
research boss aims to turbo-charge the British group's drug
discovery engine with a $300 million bet on genetics by buying a
stake in the Silicon Valley gene testing company 23andMe.

Read full article at Reuters